Selection for drug resistance results in resistance to Fas-mediated apoptosis

Blood

Volumn 89, Issue 6, 1997, Pages 1854-1861

  Landowski, Terry H ^a   Gleason Guzman, Mary C ^a   Dalton, William S ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; FAS ANTIGEN; MITOXANTRONE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CROSS RESISTANCE; DRUG RESISTANCE; ETIOLOGY; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; T CELL LEUKEMIA;

EID: 0030897001     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.1854     Document Type: Article

References (44)

1. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267:1456, 1995
2. Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013, 1994
3. D'Amico AV, McKenna WG: Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother Oncol 33:3, 1994
4. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265, 1987
5. Ueda K, Cornwall MM, Gottesman MM, Pastan I, Roninson IB, Ling V, Riordan JR: The mdrl gene, responsible for multi-drug resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141:956, 1986
6. Shustik C, Dalton WS, Gros P: P-glycoprotein-mediated multi-drug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1, 1995
7. Dalton WS, Durie BGM, Alberts DS, Gerlach JH, Cress AE: Characterization of a new drug resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125, 1986
8. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TPJ, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of Verapamil to chemotherapy. J Clin Oncol 7:415, 1989
9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385, 1993
10. Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313, 1994
11. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578, 1995
12. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650, 1992
13. Podack ER: Functional significance of two cytolytic pathways of cytotoxic T lymphocytes. J Leukoc Biol 57:548, 1995
14. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444, 1995
15. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
16. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 16:569, 1995
17. Itoh N, Nagata S: A novel protein domain required for apoptosis: Mutational analysis of human fas antigen. J Biol Chem 268:10932, 1993
18. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, Wallach D: Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO-1 prompts signaling for TNF and Fas/APO-1 effects. J Biol Chem 270:387, 1995
19. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505, 1995
20. Zhang J, Winoto A: A mouse Fas-associated protein with homology to the human Mort 1/FADD protein is essential for Fasinduced apoptosis. Mol Cell Biol 16:2756, 1996
21. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous lCE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817, 1996
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel Mort1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 85:803, 1996
23. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579, 1995
24. Baker SJ, Reddy EP: Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1, 1996
25. Green DR, Martin SJ: The killer and the executioner: How apoptosis controls malignancy. Curr Opin Immunol 7:694, 1995
26. Westendorf JJ, Lammert JM, Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 12:3466, 1995
27. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-fas antibody resulting in apoptosis. Blood 3:757, 1995
28. Futscher BW, Abbaszadegan MR, Domann F, Dalton WS: Analysis of MRP mRNA in mitoxantrone-selected, multidrug resistant human tumor cells. Biochem Pharm 47:1601, 1994
29. Friesen C, Herr I, Krammer PH, Debatin K-M: Involvement of the CD95 (APO-I/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574, 1996
30. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63:923, 1991
31. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Samashima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
32. Schattner EJ, Elkon KB, Yoo D-H, Tumang J, Krammer PH, Crow MK, Friedman SM: CD40 ligation induces APO-1/Fas expression on human B lymphocytes and facilitates apoptosis through the APO-1/Fas pathway. J Exp Med 182:1557, 1995
33. Daniel PT, Krammer PH: Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 152:5624, 1994
34. Falk MH, Trauth BC, Debatin K-M, Klas C, Gregory CD, Rickinson AB, Calendar A, Lenoir GM, Ellwart JW, Krammer PH, Bornkamm GW: Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 79:3300, 1992
35. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z: Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 166:236, 1995
36. El-Khatib M, Stanger BZ, Dogan H, Cui H, Ju S-T: The molecular mechanism of FasL-mediated cytotoxicity by CD4+ Th1 clones. Cell Immunol 163:237, 1995
37. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Moller P: Constitutive and induced expression of APO-1. a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
38. Pushkareva M, Obeid LM, Hannun YA: Ceramide: An endogenous regulator of apoptosis and growth suppression. Immunol Today 16:294, 1995
39. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R: Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals. Cell 82:405, 1995
40. Jaffrezou J-P, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, Vermeersch S, Rousse A, Laurent G: Daunorubicininduced apoptosis: Triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 15:2417, 1996
41. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin K-M, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301, 1989
42. Darzynkiewicz Z: Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J Cell Biochem 58:151, 1995
43. Massaia M, Pileri A: T cells in multiple myeloma: Is this a reliable population to count on as antitumor effector cells? Leuk Lymphoma 17:63, 1995
44. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996